Treatment persistence in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonists in clinical practice in Sweden

AIM: To compare treatment persistence in patients with type 2 diabetes initiating the glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) dulaglutide, exenatide once‐weekly (QW), liraglutide or lixisenatide in routine clinical practice in Sweden and assess clinical outcomes. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Svensson, Ann‐Marie, Toll, Anders, Lebrec, Jeremie, Miftaraj, Mervete, Franzén, Stefan, Eliasson, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953897/
https://www.ncbi.nlm.nih.gov/pubmed/33289287
http://dx.doi.org/10.1111/dom.14276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953897/
https://www.ncbi.nlm.nih.gov/pubmed/33289287
http://dx.doi.org/10.1111/dom.14276

Ejemplares similares